American Tower Corp vs Biogen Inc — how do they compare? American Tower Corp trades at $170.4 (market cap $79.00B), while Biogen Inc trades at $208.79 (market cap $30.13B). The key difference: American Tower Corp is far larger — about 2.6× Biogen Inc's market cap, and American Tower Corp pays a 4.12% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| AMT | BIIB | |
|---|---|---|
Market Cap | $79.00B | $30.13B |
Sector | Real Estate | Health |
52-Week High | $211.88 | $216.63 |
52-Week Low | $162.11 | $128.93 |
Enterprise Value | $122.53B | $37.20B |
Dividend Yield | 4.12% | — |
Signals from Pluang's Aura AI — not financial advice
American Tower Corporation (AMT) trades at $171.4, up 1.35% over the past 24 hours, with a bearish technical signal from moving averages but strong fundamental performance. The company reported Q2 2026 earnings beats, with EPS of $1.86 versus $1.57 expected, and maintains robust profitability margins, including a net income margin of 26.81%. Recent news highlights accelerated lease contract growth and a positive analyst consensus.
The outlook for AMT is supported by solid earnings growth and a 27.3% upside to the consensus price target of $206.17, though risks include interest rate sensitivity and high debt levels. Investment appeal hinges on execution in telecom infrastructure and data center expansion, balanced against macroeconomic pressures.
Biogen (BIIB) trades at $206.48, down 0.31% on the day, with a bullish technical signal supported by moving averages. The company reported Q2 2026 EPS of $3.60, beating estimates of $2.94, and raised full-year guidance, driven by growth in Alzheimer's and rare disease portfolios. Recent acquisitions like RayThera and Apellis bolster its pipeline. Revenue for 2025 was $9.89 billion with a net income margin of 13.07%, though margins have fluctuated year-over-year.
Outlook remains positive with strong analyst support (62.5% buy rating) and a consensus price target of $234.47, implying ~14% upside. Key risks include reliance on new drug launches to offset declining multiple sclerosis sales and integration challenges from acquisitions. Cash flow trends show variability, with 2026 projecting negative net cash flow due to significant investing activities.
Trailing returns across standard periods
Latest headlines on both assets
American Tower owns and operates more than 220,000 cell towers throughout the U.S., Asia, Latin America, Europe, and Africa. It also owns and/or operates 25 data centers in eight U.S. markets after acquiring CoreSite. On its towers, the company has a very concentrated customer base, with most revenue in each market being generated by just the top few mobile carriers. The company operates more than 40,000 towers in the U.S., which accounted for more than half of its total revenue in 2021. Outside the U.S., American Tower's greatest presence is in India and Brazil, where it operates roughly 75,000 and 19,000 towers, respectively. American Tower operates as a real estate investment trust.
Read more on AMT →Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →